Naporafenib

N/A

Report date: 2025/05/22 15:16:32
NMEFirst In Class

Base Information

Drug NameNaporafenib
Drug Alias NameLXH-254ERAS-254
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-Raf kinase inhibitorsSerine/threonine-protein kinase B-raf inhibitors
TargetsC-Raf kinaseSerine/threonine-protein kinase B-raf
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgErasca Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsOvarian NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A